

This item is the archived peer-reviewed author-version of:

Zonated quantification of immunohistochemistry in normal and steatotic livers

Reference:

Peleman Cédric, De Vos Winnok, Pintelon Isabel, Driessen Ann, van Eyck Annelies, Van Steenkiste Christophe, Vonghia Luisa, de Man Joris, De Winter Benedicte, Vanden Berghe Tom, ...- Zonated quantification of immunohistochemistry in normal and steatotic livers
Virchows archiv - ISSN 1432-2307 - 482(2023), p. 1035-1045
Full text (Publisher's DOI): <https://doi.org/10.1007/S00428-023-03496-8>
To cite this reference: <https://hdl.handle.net/10067/1933690151162165141>

1 **Manuscript title: Zonated quantification of immunohistochemistry in normal and steatotic livers**

2 **Short running title: Zonated immunohistochemistry in steatosis**

3 Authors: Cédric Peleman* ^(1,2), Winnok Harald De Vos ^(3, 4, 5), Isabel Pintelon ^(3, 4, 5), Ann Driessen ⁽⁶⁾,
4 Annelies Van Eyck ⁽¹⁾, Christophe Van Steenkiste ^(1,2), Luisa Vonghia ^(1,2), Joris De Man ⁽¹⁾, Benedicte
5 Yvonne De Winter ^(1,2), Tom Vanden Berghe ⁽⁷⁾, Sven Marcel Francque ^(1,2), Wilhelmus Josephus
6 Kwanten ^(1,2)

7

8 Affiliations:

9 ⁽¹⁾ Laboratory of Experimental Medicine and Pediatrics, Infla-Med Centre of Excellence, University of
10 Antwerp, Antwerp, Belgium

11 ⁽²⁾ Department of Gastroenterology and Hepatology, Antwerp University Hospital, Antwerp, Belgium

12 ⁽³⁾ Laboratory of Cell Biology & Histology, Dept. Veterinary Sciences, University of Antwerp, Antwerp,
13 Belgium

14 ⁽⁴⁾ Antwerp Centre for Advanced Microscopy (ACAM), University of Antwerp, Antwerp, Belgium

15 ⁽⁵⁾ μ NEURO Research Excellence Consortium on Multimodal Neuromics, University of Antwerp

16 ⁽⁶⁾ Department of Pathology, Antwerp University Hospital, Antwerp, Belgium

17 ⁽⁷⁾ Laboratory of Pathophysiology, University of Antwerp, Antwerp, Belgium

18

19 * Corresponding author: Cédric Peleman, Laboratory of Experimental Medicine and Pediatrics,
20 University of Antwerp. Universiteitsplein 1, 2610 Antwerpen, Belgium.
21 cedric.peleman@uantwerpen.be, T: +32 3 265 26 32, F: +32 3 265 25 78.

22

23

1 **Abstract**

2 Aims: Immunohistochemical stains (IHC) reveal differences between liver lobule zones in health and
3 disease, including non-alcoholic fatty liver disease (NAFLD). However, such differences are difficult
4 to accurately quantify. In NAFLD, the presence of lipid vacuoles from macrovesicular steatosis further
5 hampers interpretation by pathologists. To resolve this, we applied a zonal image analysis method to
6 measure the distribution of hypoxia markers in the liver lobule of steatotic livers.

7 Methods and results: The hypoxia marker pimonidazole was assessed with IHC in the livers of male
8 C57BL/6J mice on standard diet or choline-deficient L-amino acid-defined high-fat diet mimicking
9 NAFLD. Another hypoxia marker, carbonic anhydrase IX, was evaluated by IHC in human liver tissue.
10 Liver lobules were reconstructed in whole slide images and staining positivity was quantified in different
11 zones in hundreds of liver lobules. This method was able to quantify the physiological oxygen gradient
12 along hepatic sinusoids in normal livers and panlobular spread of the hypoxia in NAFLD, and to
13 overcome the pronounced impact of macrovesicular steatosis on IHC. In a proof-of-concept study with
14 assessment of the parenchyma between centrilobular veins in human liver biopsies carbonic anhydrase
15 IX could be quantified correctly as well.

16 Conclusions: The method of zoned quantification of IHC objectively quantifies the difference in zonal
17 distribution of hypoxia markers (used as an example) between normal and NAFLD livers both in whole
18 liver as well as in liver biopsy specimens. It constitutes a tool for liver pathologists to support visual
19 interpretation and estimate the impact of steatosis on IHC results.

20

21 **Keywords**

22 Non-alcoholic fatty liver disease, immunohistochemistry, liver zonation, quantitative evaluation,
23 hypoxia

1 **Introduction**

2 The liver parenchyma is organised into functional zones, wherein hepatocytes and nonparenchymal cell
3 types display different phenotypes depending on their localisation along the liver sinusoids and the
4 circadian rhythm.[1] In various disease states this homeostasis is perturbed, with pathogenic alterations
5 occurring in specific zones or the entirety of the liver lobule. This zonation is widely studied by means
6 of histology and antibody-based detection of biomarkers, but changes are difficult to quantify. For
7 instance, semi-quantitative scoring of immunohistochemistry (IHC) in the centrolobular or periportal
8 zones of the liver lobule can be prone to bias, especially since those zones are not clearly demarcated.[2–
9 5] Quantitative IHC is not yet routine practice in the histopathology field, although efforts are
10 undertaken in digital pathology.[6] The issue of zonal quantification in the liver, however, has not been
11 sufficiently addressed.

12 Non-alcoholic fatty liver disease (NAFLD), regarded as the hepatic manifestation of the metabolic
13 syndrome, is recognised as a major cause of cirrhosis and second indication for liver transplantation in
14 the US.[7–9] Given its epidemic proportions, affecting roughly a quarter of the global adult population,
15 much (pre)clinical research is conducted to identify druggable targets.[10] NAFLD is defined by
16 presence of vesicles of fat (mainly triglycerides) in the hepatocytes, termed macrovesicular steatosis,
17 which form blank spaces created by hepatocellular lipid vacuoles filling the cytoplasm. Evidently,
18 severe forms of steatosis hamper the interpretation and quantification of the percentage of positively
19 stained area, especially for cytoplasmic markers, as well as comparison with non-steatotic controls.[11]
20 Therefore, we applied a method to zonally quantify the distribution of epitopes within the liver lobule,
21 even in the presence of steatosis, using hypoxia markers as examples in a preclinical model and human
22 liver specimens.

23

24

25

1 **Materials and methods**

2 *Animal experiments and Immunohistochemistry*

3 C57BL/6J male mice (Janvier Labs, Le Genest-Saint-Isle, France), housed in 12 hour light-dark cycles
4 and fed ad libitum, were randomised to receive either the choline-deficient L-amino acid defined high-
5 fat diet (CDAHFD, A06071302, Research Diets, New Brunswick, NJ, USA) or standard diet (controls)
6 for three weeks. Subsequently, animals received an intraperitoneal injection of pimonidazole
7 (100mg/kg) one hour prior to sacrifice (n=6 per group). Pimonidazole is a 2-nitroimidazole which is
8 reductively activated in hypoxic cells and forms stable adducts with thiol groups of proteins, peptides
9 and amino acids.[12] Serial sections of formalin-fixed paraffin-embedded (FFPE) liver tissue (5µm
10 thick) were stained with haematoxylin-eosin (H&E) stain, as well as IHC for glutamine synthetase (GS)
11 and pimonidazole adducts (two sets of serial sections per animal). Briefly, heat-induced epitope retrieval
12 was performed with pressure cooker for GS in 0.01M sodium citrate buffer (pH 6.0); endogenous
13 peroxidases and biotin were blocked. Nonspecific binding was blocked with 10% normal goat serum.
14 Primary antibodies for pimonidazole (PAb2627, 1:750, Hypoxyprobe, Burlington, MA, USA) and GS
15 (ab73593, 1:500, Abcam, Cambridge, UK) were incubated overnight at room temperature. Binding of
16 the primary antibody was visualised with VECTASTAIN® ABC-HRP Kit (PK-4001, Vector
17 Laboratories, Newark, CA, USA) and 3,3'-diaminobenzidine (DAB, D8001, Sigma-Aldrich, St. Louis,
18 MO, USA). The ARRIVE guideline for animal pre-clinical studies was used during the preparation of
19 the manuscript.[13]

20 *Human liver specimens and Immunohistochemistry*

21 We studied FFPE human liver tissue obtained from a donor-liver with steatosis, which was rejected
22 because of a high degree of steatosis (>30%). Moreover, percutaneous core needle biopsy material was
23 obtained from three patients referred to the outpatient Hepatology clinic at the Antwerp University
24 Hospital between 2015 and 2019 for mildly elevated transaminase levels. The study was approved by
25 the Ethical Committee of the Antwerp University Hospital (references 6/25/125 and 15/21/227) and
26 patients gave written consent for the collection of material. Serial sections of liver tissue (5µm thick)

1 were stained with IHC for GS (ab73593, 1:500, Abcam, UK) and carbonic anhydrase IX (CAIX, PA1-
2 16592, Invitrogen, US) as described above.

3 *Whole slide imaging acquisition and data processing*

4 Slides from all murine and human liver specimens were digitalised using the Zeiss Axioscan Z1
5 automated whole slide scanner (Zeiss, Germany) using a 20x objective lens (pixel size 0,22 x 0,22 µm).
6 A whole slide image was loaded into FIJI image processing freeware and subjected to the image analysis
7 script described in supplemental materials.[14] Briefly, colour deconvolution was applied on
8 pimonidazole IHC to isolate the DAB signal which was binarised by means of the Percentile
9 autothreshold algorithm to identify positively stained area.[15, 16] A separate segmentation based on
10 manual thresholding (grey values of 190 and above) and subsequent size (53-580µm) and circularity
11 (0.5-1.00) filtering was performed to annotate the majority of lipid vacuoles.[17] These parameters for
12 lipid vacuole detection minimise false-positive selections (only clear macrovesicular steatosis), while
13 accepting more false-negatives, and were applied uniformly on all images to avoid operator-dependent
14 bias. Liver lobules are organised according to a principle that is best described by Voronoi diagrams.[5,
15 18] Hence, we implemented a routine that delineates all lobules by means of Voronoi tessellation after
16 manual annotation of central veins, based on morphology on H&E and IHC for GS, and the liver capsule.
17 GS is a well-known marker of hepatocytes adjacent to the centrolobular vein.[19] Next, pixels within
18 each lobule were assigned with a relative distance value (0 at the lobular edge to 1 in the centrolobular
19 vein) and visualised with a corresponding colour for each relative distance using the look-up table '16
20 colors'. The results were processed in RStudio, expanded with the R-package "dplyr" for grouped
21 summary statistics to produce heatmaps and calculate the zonation of pimonidazole positivity.[20]

22 *'Digital' biopsies of a preclinical NAFLD model*

23 In clinical practice, there is more availability of needle biopsy material but reconstruction of whole liver
24 lobules is difficult due to the small amount of liver tissue in that setting, the limited number of
25 centrolobular veins and the absence of the liver capsule in the biopsy specimen. The method of zonated
26 quantification of IHC was hence adapted for use in needle biopsy specimens. Indeed, the relative

1 distance can be correctly assessed in parenchyma directly connecting different centrolobular veins, so-
2 called centro-central tracts, which are available in needle biopsy specimens. Based on the anatomy of
3 the Kiernan's lobule the portal area will be situated between the centrolobular veins in the middle of the
4 centro-central tracts. We tested this approach by performing 'digital' liver biopsies in the murine liver
5 slides analysed above, in order to compare the analysis in whole liver slides with the centro-central
6 approach. Random 'digital' biopsies (rectangular areas of 300µm x 50µm in size, equivalent to a small
7 liver biopsy) were hence selected from whole liver slides of C57BL/6J male mice fed CDAHFD or
8 standard diet (controls) and analysed isolatedly. These specimens of liver tissue contained 3 to 5
9 centrolobular veins to reconstruct the relative distance maps.

10 *Statistical analyses*

11 Proportions of pimonidazole positive areas and ratios thereof in periportal vs. centrolobular zones from
12 all laboratory mice were expressed as mean±standard deviation. Differences between normal and
13 diseased subjects were assessed for statistical significance with the Mann-Whitney U test. Means of
14 periportal vs. centrolobular ratio assessed in whole liver slides and centro-central tracts were compared
15 by paired T-test. Intraclass correlation coefficients (ICC) for absolute agreement were calculated to
16 examine agreement between the two methods of zonated quantification of hypoxia marker pimonidazole
17 obtained from analysis of whole liver slides and the 'digital' liver biopsies in the same experimental
18 subjects. ICC values were interpreted as follows: 0-0.2 corresponds to poor agreement, 0.3-0.4
19 corresponds to fair agreement, 0.5-0.6 corresponds to moderate agreement, 0.7-0.8 corresponds to strong
20 agreement, and >0.8 indicates near perfect agreement.[21] Statistical analysis was performed with SPSS
21 (version 28; IBM, USA). All figures were generated using GraphPad Prism (version 9.0; GraphPad
22 Software, USA).

23

1 **Results**

2 *Histology of a preclinical NAFLD model and IHC for pimonidazole adducts shows panlobular hypoxia* 3 *in NASH*

4 After three weeks all mice on CDAHFD displayed the features of non-alcoholic steatohepatitis (NASH),
5 as opposed to the controls.[22] In healthy livers, the physiological oxygen gradient was demonstrated
6 by corresponding pimonidazole adducts with positivity in the centrolobular area attenuating towards the
7 periportal triads (Fig. 1A upper panel).[23] However, in NASH the staining for pimonidazole adducts
8 was more equally present throughout the whole liver lobule but interrupted by lipid vacuoles, in
9 agreement with other reports (Fig. 1A upper panel).[24, 25] It is known that steatosis in this model is
10 more pronounced in the periportal zones (Fig. 1A middle panel).[22] GS expression was limited to
11 hepatocytes around the centrolobular veins, both in normal and NASH livers (Fig. 1A lower panel). The
12 DAB signal of pimonidazole IHC was presented as a heatmap to demonstrate widespread intense
13 positive staining of the liver parenchyma in CDAHFD compared to more focal positivity around
14 centrilobular veins in controls (Fig. 1B upper panel). Of note, no staining signal was detected upon
15 omission of the primary antibody directed against pimonidazole adducts (Fig. S1). Subsequently,
16 centrolobular veins served as seeds for liver lobule reconstructions and pixels within each lobule
17 received a relative distance value ranging from 0 (at the lobular edge) to 1 (in the centrolobular vein).
18 This relative distance map is illustrated by the lower panel of Fig. 1B, wherein each colour represents
19 points with the same relative distance between centre (centrolobular veins annotated in white) and edge
20 (annotated in black) of each constructed lobule.

21

22 *Zonated quantification of immunohistochemistry confirms the periportal increase in pimonidazole* 23 *positivity in a preclinical NASH model vs normal livers*

24 Next, the pimonidazole positive area occupancy (area %) and macrovesicular steatotic area occupancy
25 (area %) were quantified as a function of the relative distance within individual liver lobules of all
26 laboratory mice included in this study (Figures 2A and 2B). The amount of pimonidazole positive area

1 is diluted by the presence of macrovesicular steatosis (which itself is not uniformly distributed) since
2 lipid vacuoles occupy space. However, when these lipid vacuoles were excluded from the analysis, the
3 amount of pimonidazole positive area was significantly higher in the periportal zone of the lobules from
4 mice on CDAHFD compared to controls ($p < 0.01$; Fig. 2C).

5 Moreover, to express the zonal distribution in a single value, the ratio of pimonidazole positive areas in
6 periportal vs. centrolobular thirds of all lobules was calculated without exclusion of lipid vacuoles. This
7 ratio was low in healthy livers, thereby reflecting the physiological hypoxia towards the centre of
8 Kiernan's liver lobule, but was significantly higher in NASH livers in accordance with panlobular
9 positivity ($p < 0.001$; Fig. 2D).

10

11 *'Digital' biopsies of a preclinical NAFLD model*

12 Analysis of 'digital' biopsies of all laboratory mice of the preclinical NAFLD model revealed significant
13 periportal pimonidazole positivity in centro-central tracts of NASH livers compared to controls, after
14 exclusion of lipid vacuoles (Fig. 3A-C). Therefore, the analysis of the liver parenchyma between
15 centrolobular veins detected similar trends as whole liver slides. The means of periportal vs.
16 centrolobular ratios differed significantly between the two methods ($p = 0.004$ when including lipid
17 droplets, $p = 0.003$ when excluding lipid droplets), indicating the presence of a systematic difference
18 with higher ratios in the centro-central approach compared to whole liver slides (Fig. S2). In other words,
19 the lobular gradient of pimonidazole positivity is less steep when analysing the centro-central tracts,
20 partly due to higher periportal pimonidazole positive area, compared to whole liver slides. In addition,
21 the ICC between the two methods showed moderate to strong agreement for IHC for pimonidazole in
22 the preclinical NAFLD model: ICC absolute agreement 0.823 (95% CI 0.486-0.930, $p < 0.001$) when
23 including lipid droplets, ICC absolute agreement 0.866 (95% CI 0.568-0.949, $p < 0.001$) when excluding
24 lipid droplets.

25

26 *Application of zoned quantification of immunohistochemistry in human liver material*

1 An area of a liver resection specimen with steatosis was assessed with IHC for CAIX (Fig. 4A). This
2 hypoxia marker displayed foci of strong positivity in the centrolobular area (Fig. 4B). As proof of
3 concept, liver lobules were reconstructed (Fig. 4C) and IHC for CAIX was quantified in different zones
4 (Fig. 4D), thereby confirming the centrolobular nature of this epitope through accurate, objective
5 quantification of the staining pattern.

6 Finally, in order to further test the centro-central approach in humans, three human needle biopsy
7 specimens were stained with IHC and revealed panlobular, intense positivity for CAIX in two NASH
8 subjects, compared to one control (Fig. 5A upper panels). Next, distance maps were reconstructed
9 between centrolobular veins (Fig. 5A lower panels) and the staining pattern of CAIX was plotted in
10 these centro-central tracts (Fig. 5B). The distribution of CAIX was even in different zones of the liver
11 lobule with a higher proportion of positive area in the NASH patients compared to control. Fig S3
12 displays the whole slide images of the three needle biopsy specimens.

1 **Discussion**

2 The method described in this manuscript quantifies the location of IHC stains within the liver lobule in
3 normal and steatotic livers, using hypoxia markers as examples. After reconstruction of lobules IHC
4 staining patterns are quantified according to the relative distance. Interpretation by pathologists is of
5 paramount relevance, but accurate quantification supports conclusions. Moreover, instead of showing
6 only representative images or analysing ‘random’ fields per tissue slide which can introduce observer
7 bias, this method analyses and represents a staining pattern of hundreds of lobules in an objective way.
8 The exclusion of areas occupied by lipid droplets enhanced the interpretation of the zonal staining
9 patterns, compared with the whole liver slide area containing lipid vacuoles which are by their nature
10 unable to stain positively. It enables the pathologist to better assess the (zonal) impact of steatosis on
11 IHC results. In addition, ‘digital’ biopsies drawn from mice livers demonstrate moderate-to-strong
12 agreement between whole liver analysis for pimonidazole compared to more limited liver tissue. The
13 ‘digital’ biopsies represent only a small part of the liver tissue and increasing the size/length or number
14 of those samples could further enhance the agreement with whole liver analysis. Subsequent proof-of-
15 concept in a human surgical resection specimen and needle biopsy specimens another hypoxia marker
16 suggests that this method could also be used in the human, clinical pathology setting. This can be further
17 explored in large cohorts of human needle biopsy specimens stained with IHC for various epitopes.
18 Importantly, in this study steatotic livers and hypoxia markers serve to demonstrate this objective zonal
19 IHC quantification, which could be applied to various epitopes in normal livers and multiple hepatologic
20 diseases.

21 Within the healthy liver lobule hepatocytes differentiate to perform very different enzymatic and
22 metabolic functions depending on their position along the sinusoid. For example, periportal hepatocytes
23 perform gluconeogenesis, oxidation of fatty acids and ammonia detoxification, whereas their perivenous
24 counterparts express enzymes required for glycolysis, lipogenesis and drug metabolism. Detailed single-
25 cell spatial reconstruction revealed that functional separation into nine layers of hepatocytes could be
26 more accurate than the traditional three lobular zones.[26] Regulators of the phenomenon of zonation
27 are the gradients of oxygen, nutrients, hormones, as well as various molecular pathways (*e.g.* Wnt/ β -

1 catenin, hedgehog), but knowledge of these regulators is incomplete.[19, 27] Functional organisation of
2 the liver lobule is perturbed in pathologic conditions with nearly every disease entity displaying a
3 distinct topography. Histological abnormalities in NAFLD, for instance, mostly start in the centrolobular
4 area, which is also severely affected in ischemic hepatitis and drug-induced liver injury.[19, 28]
5 Conversely, the inflammatory infiltrate of auto-immune hepatitis radiates from the portal triads to
6 infiltrate the parenchyma.[29] Topography of histological abnormalities and IHC stains supports
7 pathologists to make the correct diagnosis (or combinations thereof) in individual patients. The proposed
8 method could accurately describe the location and extent of histological abnormalities and evolution
9 within disease progression/regression in routine practice after validation.

10 Moreover, the method of zoned quantification of IHC could be applied more readily in the setting of
11 clinical trials and translational research. IHC stains typically provide qualitative data and descriptions,
12 which semi-quantitative scoring can transform into data amenable to statistical analysis in the setting of
13 research, through separation into ordinal classes.[30] However, semi-quantitative scoring has limitations
14 since it relies on labour-intensive, manual observations susceptible to some levels of observer
15 variability.[3, 4] For instance, the H-score combines the percentage of HER2 positive cells and their
16 stain intensity, visually estimated by the pathologist, to guide treatment decisions.[31] The results of
17 this subjective scoring are influenced by histological expertise and agreement could be improved by
18 computer-aided digital microscopy.[32, 33] Moreover, the human visual system has limited ability to
19 detect subtle differences, especially in the low intensity range.[34, 35] Hence, image analysis systems
20 that yield continuous data, such as the zoned quantification method presented above, may assist
21 pathologists and researchers in detecting subtle differences.

22 Indeed, the field of digital pathology has enjoyed much interest in the last decade of (pre)clinical liver
23 research both autonomous and in conjunction with classical pathology reading. Most of the research
24 effort has focused on artificial intelligence imaging for automated detection and quantification of
25 histological hallmarks of disease, *i.e.* macrovesicular steatosis, ballooning, lobular inflammation and
26 fibrosis in NAFLD.[6, 36–39] Various machine learning algorithms based on deep convolutional
27 networks are trained to count those features. For instance, Naoumov *et al.* recently demonstrated that

1 reanalysis of human liver biopsies with artificial intelligence revealed an antifibrotic effect of tropifexor
2 that was not evidenced by conventional scoring.[40] Hence, these systems might allow for a more
3 granular assessment of (drug-induced) changes in histological features. Of note, compared to degree of
4 positive area, semi-quantitative scoring of liver biopsy remains more reliant on the training sets based
5 on annotation by multiple human pathologists.[37, 41] However, to the best of our knowledge, accurate
6 evaluation of zonation within the liver lobule of those key histological features has not been incorporated
7 in the existing systems. The method presented herein could be enhanced with automated detection of
8 centrilobular veins to allow for higher throughput. Next, the aspect of liver zonation could be added to
9 digital pathology to describe in more detail the distribution of key histological hallmarks and different
10 epitopes assessed with IHC. Alternative methods to assess zonation would be (rather cumbersome)
11 manual counting of positive hepatocytes in rows radiating outwards from the central veins or subjective
12 estimation of the centrilobular or periportal zones.[2, 42] The latter is less accurate given that the lobular
13 zones are not visibly anatomically delineated.

14 Furthermore, in this study we chose to quantify the percentage of IHC positive area in relation to the
15 lobular regions. Alternatively, machine learning and pixel classifiers could have counted the percentage
16 of positive hepatocytes to use a cell-based quantification instead of the pixel-based approach. Cell-based
17 automated detection has been employed for quantification of hypoxia markers in other cell types and
18 can differentiate between nuclear and cytoplasmic positivity.[43, 44] However, such cell-based
19 recognition might be challenging in steatosis given the abundance of lipid vacuoles which are actually
20 hepatocytes without stainable cytoplasm and whose nuclei can be situated outside the sectioning
21 plane.[45] Nevertheless, cell-based and pixel-based methods of quantification could be mutually
22 supportive.

23 A limitation of the method presented herein is that compound lobules, tangential sectioning of lobules
24 and tears in whole liver tissue slides can reduce accurate reconstruction of liver lobules. These
25 limitations are intrinsic to the 2D representation of 3D structures and could be partially resolved by
26 whole liver serial sectioning and 3D reconstruction of lobules. Validation of this method for the
27 detection of zonation of other epitopes is needed. Moreover, the CDAHFD dietary model induces

1 histological abnormalities of NASH but lacks other features of the metabolic syndrome, such as visceral
2 adiposity and systemic insulin resistance.[22] Indeed, the pathophysiology of NAFLD is very complex
3 with intrahepatic alterations, such as vascular alterations, lipotoxicity, cell death, immune cell
4 infiltration and important cellular matrix alterations with liver fibrosis, which are intricately related to
5 the systemic alterations of the metabolic syndrome.[46–50] Choline-deficient diets, such as the
6 CDAHFD, are considered and accepted liver-centred models with pronounced steatosis to exemplify
7 the method of zoned IHC quantification.[51] The pattern of liver fibrosis was not a subject in the
8 present study. In addition, the use of the proposed method in other liver diseases, *e.g.* alcohol related
9 liver disease and chronic hepatitis C which can also bear macrovesicular steatosis as a hallmark, is
10 worthwhile to investigate. Moreover, in this study we used the avidin-biotin complex (ABC) system to
11 visualise epitopes, whereas a two-step method based on a horse radish peroxidase (HRP) labelled
12 polymer conjugated with secondary antibodies (*e.g.* EnVision+ system) is increasingly used. This highly
13 sensitive assay avoid interference from endogenous biotin, but comes at greater cost per unit of detection
14 system.[52] In our study endogenous biotin was blocked and a negative control for the ABC detection
15 system excluded false positivity due to any remaining endogenous biotin. The quantification method for
16 DAB positivity could be applied for both HRP-based detection systems. Finally, the strength is the use
17 of a simple algorithm combining previously described open-source methods that is manageable by non-
18 experts in advanced image processing.

19 In conclusion, this method enables objective zonal quantification of IHC for hypoxia marker
20 pimonidazole in liver in a preclinical model, even when severely steatotic, and can improve
21 interpretation of the marker of interest. We provide proof-of-concept that this method could also be
22 applied to human needle biopsies, paving the way for its use in the clinical pathology setting.

23

1 **Acknowledgements**

2 We thank Sofie Thys for technical assistance with scanning of the slides. This study was funded by the
3 Fund for Scientific Research (FWO) Flanders (1171121N), research grants of the University of Antwerp
4 (GOA project: FFB180348/36572) and the Belgian Association for the Study of the Liver (BASL basic
5 research award 2020 supported by Gilead).

6

7 **Abbreviations**

8 ABC, avidin-biotin complex; CAIX, carbonic anhydrase IX; CDAHFD, choline-deficient L-amino acid-
9 defined high-fat diet; CL, centrolobular; DAB, 3,3'-diaminobenzidine; FFPE, formalin-fixed paraffin-
10 embedded; GS, glutamine synthetase; H&E, haematoxylin-eosin; HRP, horse radish peroxidase; ICC,
11 intraclass correlation coefficient; IHC, immunohistochemistry; NAFLD, non-alcoholic fatty liver
12 disease; NASH, non-alcoholic steatohepatitis; Pimo, pimonidazole; PP, periportal

13

14 **List of online Supporting Information**

15 Plugin for FIJI, title: Zonated_portality_measurement.ijm. Also available at:
16 https://github.com/DeVosLab/Steatosis_ZonatedPortality

17 Supplementary Figure S1. Comparison of ratio of periportal vs. centrolobular Pimonidazole positive
18 area assessed in whole liver slides and centro-central tracts in a preclinical NAFLD model.

19 Supplementary Figure S2. Whole slide liver images of IHC on human needle biopsy specimens.

20

21

22

23

1 **Statements and Declarations**

2 Data Availability Statement: The whole slide image data used to support the findings of this study are
3 available from the corresponding author at cedric.peleman@uantwerpen.be upon request.

4 Funding: C.P. received funding from the Fund for Scientific Research (FWO) Flanders (1171121N).
5 This study was funded by research grants of the University of Antwerp (GOA project:
6 FFB180348/36572) and the Belgian Association for the Study of the Liver (BASL basic research award
7 2020 supported by Gilead). The funders had no role in study design, collection, analysis or interpretation
8 of data, or writing of the report.

9 Conflict of interest disclosure: All authors declare that they have no financial or non-financial interests
10 related to this manuscript.

11 Ethics Approval and Consent to Participate: All animal experiment presented in this work were approved
12 by the Ethical Committee of Animal Experimentation of the University of Antwerp (Protocol number:
13 2019-42). All animals received humane care in accordance with the "Guide for the Care and Use of
14 Laboratory Animals (Eighth Edition)" prepared by the National Academy of Sciences and published by
15 the National Institutes of Health. Human data reported in this study was obtained from patients who
16 gave written consent for the collection of material; the protocols were conformed to the ethical
17 guidelines of the latest version of the Declaration of Helsinki. The study was approved by the Ethical
18 Committee of the Antwerp University Hospital (references 6/25/125 and 15/21/227).

19 Authors' contributions: C.P., W.H.D., T.V., W.J.K. conceptualization and design of research; C.P., J.D.,
20 A.V. performed experiments; C.P., W.H.D. software and formal analysis; C.P. drafted manuscript and
21 prepared figures; I.P. methodology; W.H.D., I.P., A.D., A.V., C.V., L.V., J.D., B.D., T.V. S.M.F. and
22 W.J.K. edited and revised manuscript; C.P., W.H.D., I.P., A.D., A.V., C.V., L.V., J.D., B.D., T.V.,
23 S.M.F. and W.J.K. seen and approved final version of manuscript.

24

1 **References**

- 2 1. Droin C, Kholtei J El, Bahar Halpern K, et al (2021) Space-time logic of liver gene expression
3 at sub-lobular scale. *Nat Metab* 3:43–58. <https://doi.org/10.1038/s42255-020-00323-1>
- 4 2. Seki S, Kitada T, Yamada T, et al (2002) In situ detection of lipid peroxidation and oxidative
5 DNA damage in non-alcoholic fatty liver diseases. *J Hepatol* 37:56–62.
6 [https://doi.org/10.1016/S0168-8278\(02\)00073-9](https://doi.org/10.1016/S0168-8278(02)00073-9)
- 7 3. Meyerholz DK, Beck AP (2018) Principles and approaches for reproducible scoring of tissue
8 stains in research. *Lab Investig* 98:844–855. <https://doi.org/10.1038/s41374-018-0057-0>
- 9 4. Walker RA (2006) Quantification of immunohistochemistry - Issues concerning methods,
10 utility and semiquantitative assessment I. *Histopathology* 49:406–410.
11 <https://doi.org/10.1111/j.1365-2559.2006.02514.x>
- 12 5. Lau C, Kalantari B, Batts KP, et al (2021) The Voronoi theory of the normal liver lobular
13 architecture and its applicability in hepatic zonation. *Sci Rep* 11:9343.
14 <https://doi.org/10.1038/s41598-021-88699-2>
- 15 6. Taylor-Weiner A, Pokkalla H, Han L, et al (2021) A Machine Learning Approach Enables
16 Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. *Hepatology*
17 74:133–147. <https://doi.org/10.1002/hep.31750>
- 18 7. Setiawan VW, Stram DO, Porcel J, et al (2016) Prevalence of chronic liver disease and
19 cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort.
20 *Hepatology* 64:1969–1977. <https://doi.org/10.1002/hep.28677>
- 21 8. Goldberg D, Ditah IC, Saeian K, et al (2017) Changes in the Prevalence of Hepatitis C Virus
22 Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With
23 Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. *Gastroenterology*
24 152:1090–1099. <https://doi.org/10.1053/j.gastro.2017.01.003>
- 25 9. Wong RJ, Aguilar M, Cheung R, et al (2015) Nonalcoholic steatohepatitis is the second leading

- 1 etiology of liver disease among adults awaiting liver transplantation in the United States.
2 Gastroenterology 148:547–555. <https://doi.org/10.1053/j.gastro.2014.11.039>
- 3 10. Younossi ZM, Koenig AB, Abdelatif D, et al (2016) Global epidemiology of nonalcoholic fatty
4 liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology
5 64:73–84. <https://doi.org/10.1002/hep.28431>
- 6 11. Ghallab A, Myllys M, Friebel A, et al (2021) Spatio-temporal multiscale analysis of western
7 diet-fed mice reveals a translationally relevant sequence of events during NAFLD progression.
8 Cells 10:2516. <https://doi.org/10.3390/cells10102516>
- 9 12. Raleigh JA, Koch CJ (1990) Importance of thiols in the reductive binding of 2-nitroimidazoles
10 to macromolecules. Biochem Pharmacol 40:2457–2464. [https://doi.org/10.1016/0006-](https://doi.org/10.1016/0006-2952(90)90086-Z)
11 [2952\(90\)90086-Z](https://doi.org/10.1016/0006-2952(90)90086-Z)
- 12 13. Percie N, Hurst V, Ahluwalia A, et al (2020) The ARRIVE guidelines 2.0: updated guidelines
13 for reporting animal research. BMJ Open Sci 1–7. <https://doi.org/10.1136/bmjos-2020-100115>
- 14 14. Schindelin J, Arganda-Carreras I, Frise E, et al (2012) Fiji: An open-source platform for
15 biological-image analysis. Nat Methods 9:676–682. <https://doi.org/10.1038/nmeth.2019>
- 16 15. Ruifrok AC, Johnston DA (2001) Quantification of histochemical staining by color
17 deconvolution. Anal Quant Cytol Histol 23, 291–299 10–27
- 18 16. Doyle W (1962) Operations Useful for Similarity-Invariant Pattern Recognition. J ACM
19 9:259–267. <https://doi.org/10.1145/321119.321123>
- 20 17. Munsterman ID, van Erp M, Weijers G, et al (2019) A Novel Automatic Digital Algorithm that
21 Accurately Quantifies Steatosis in NAFLD on Histopathological Whole-Slide Images. Cytom
22 Part B 96:521–528. <https://doi.org/10.1002/cyto.b.21790>
- 23 18. Schwen LO, Homeyer A, Schwier M, et al (2016) Zonated quantification of steatosis in an
24 entire mouse liver. Comput Biol Med 73:108–118.
25 <https://doi.org/10.1016/j.combiomed.2016.04.004>

- 1 19. Panday R, Monckton CP, Khetani SR (2022) The Role of Liver Zonation in Physiology,
2 Regeneration, and Disease. *Semin Liver Dis* 42:1–16. <https://doi.org/10.1055/s-0041-1742279>
- 3 20. R Core Team (2018) R: A Language and Environment for Statistical Computing. In: R Found.
4 Stat. Comput. Vienna. <https://www.r-project.org>
- 5 21. Landis JR, Koch GG (1977) The Measurement of Observer Agreement for Categorical Data.
6 *Biometrics* 33:159–174. <https://doi.org/10.2307/2529310>
- 7 22. Matsumoto M, Hada N, Sakamaki Y, et al (2013) An improved mouse model that rapidly
8 develops fibrosis in non-alcoholic steatohepatitis. *Int J Exp Pathol* 94:93–103.
9 <https://doi.org/10.1111/iep.12008>
- 10 23. Kietzmann T (2019) Liver zonation in health and disease: Hypoxia and hypoxia-inducible
11 transcription factors as concert masters. *Int J Mol Sci* 20:2347.
12 <https://doi.org/10.3390/ijms20092347>
- 13 24. Mantena SK, Vaughn DP, Andringa KK, et al (2009) High fat diet induces dysregulation of
14 hepatic oxygen gradients and mitochondrial function in vivo. *Biochem J* 417:183–193.
15 <https://doi.org/10.1042/BJ20080868>
- 16 25. Meng L, Goto M, Tanaka H, et al (2021) Decreased Portal Circulation Augments Fibrosis and
17 Ductular Reaction in Nonalcoholic Fatty Liver Disease in Mice. *Am J Pathol* 191:1580–1591.
18 <https://doi.org/10.1016/j.ajpath.2021.06.001>
- 19 26. Ben-Moshe S, Shapira Y, Moor AE, et al (2019) Spatial sorting enables comprehensive
20 characterization of liver zonation. *Nat Metab* 1:899–911. [https://doi.org/10.1038/s42255-019-](https://doi.org/10.1038/s42255-019-0109-9)
21 [0109-9](https://doi.org/10.1038/s42255-019-0109-9)
- 22 27. Paris J, Henderson NC (2022) Liver zonation, revisited. *Hepatology* 76:1219–1230.
23 <https://doi.org/10.1002/hep.32408>
- 24 28. Cunningham RP, Porat-Shliom N (2021) Liver Zonation – Revisiting Old Questions With New
25 Technologies. *Front Physiol* 12:1–17. <https://doi.org/10.3389/fphys.2021.732929>

- 1 29. Czaja AJ, Carpenter HA (1993) Sensitivity, specificity, and predictability of biopsy
2 interpretations in chronic hepatitis. *Gastroenterology* 105:1824–1832.
3 [https://doi.org/10.1016/0016-5085\(93\)91081-R](https://doi.org/10.1016/0016-5085(93)91081-R)
- 4 30. Meyerholz DK, Beck AP (2018) Fundamental Concepts for Semiquantitative Tissue Scoring in
5 Translational Research. *ILAR J* 59:13–17. <https://doi.org/10.1093/ilar/ily025>
- 6 31. McCarty K, Szabo E, Flowers J, et al (1986) Use of a monoclonal anti-estrogen receptor
7 antibody in the immunohistochemical evaluation of human tumors. *Cancer Res* 46:4244–4248
- 8 32. Gavrielides MA, Gallas BD, Lenz P, et al (2011) Observer variability in the interpretation of
9 HER2/neu immunohistochemical expression with unaided and computer-aided digital
10 microscopy. *Arch Pathol Lab Med* 135:233–242. <https://doi.org/10.5858/135.2.233>
- 11 33. Skaland I, Øvestad I, Janssen EAM, et al (2008) Digital image analysis improves the quality of
12 subjective HER-2 expression scoring in breast cancer. *Appl Immunohistochem Mol Morphol*
13 16:185–190. <https://doi.org/10.1097/PAI.0b013e318059c20c>
- 14 34. Rimm DL, Giltneane JM, Moeder C, et al (2007) Bimodal population or pathologist artifact?
15 [1]. *J Clin Oncol* 25:2487–2488. <https://doi.org/10.1200/JCO.2006.07.7537>
- 16 35. Camp RL, Dolled-Filhart M, King BL, Rimm DL (2003) Quantitative analysis of breast cancer
17 tissue microarrays shows that both high and normal levels of HER2 expression are associated
18 with poor outcome. *Cancer Res* 63:1445–1448
- 19 36. Liu F, Goh GBB, Tiniakos D, et al (2020) qFIBS: An Automated Technique for Quantitative
20 Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic
21 Steatohepatitis. *Hepatology* 71:1953–1966. <https://doi.org/10.1002/hep.30986>
- 22 37. Brunt EM, Clouston AD, Goodman Z, et al (2022) Complexity of ballooned hepatocyte feature
23 recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. *J*
24 *Hepatol* 76:1030–1041. <https://doi.org/10.1016/j.jhep.2022.01.011>
- 25 38. Forlano R, Mullish BH, Giannakeas N, et al (2020) High-Throughput, Machine Learning–

- 1 Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From
2 Patients With Nonalcoholic Fatty Liver Disease. *Clin Gastroenterol Hepatol* 18:2081–2090.
3 <https://doi.org/10.1016/j.cgh.2019.12.025>
- 4 39. Bosch J, Chung C, Carrasco-Zevallos OM, et al (2021) A Machine Learning Approach to Liver
5 Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
6 *Hepatology* 74:3146–3160. <https://doi.org/10.1002/hep.32087>
- 7 40. Naoumov N V., Brees D, Loeffler J, et al (2022) Digital pathology with artificial intelligence
8 analyses provides greater insights into treatment-induced fibrosis regression in NASH. *J*
9 *Hepatol* DOI: 10.1016/j.jhep.2022.06.018. <https://doi.org/10.1016/j.jhep.2022.06.018>
- 10 41. Davison BA, Harrison SA, Cotter G, et al (2020) Suboptimal reliability of liver biopsy
11 evaluation has implications for randomized clinical trials. *J Hepatol* 73:1322–1332.
12 <https://doi.org/10.1016/j.jhep.2020.06.025>
- 13 42. Arteel GE, Iimuro Y, Yin M, et al (1997) Chronic enteral ethanol treatment causes hypoxia in
14 rat liver tissue in vivo. *Hepatology* 25:920–926. <https://doi.org/10.1002/hep.510250422>
- 15 43. Zaidi M, Fu F, Cojocari D, et al (2019) Quantitative Visualization of Hypoxia and Proliferation
16 Gradients Within Histological Tissue Sections. *Front Bioeng Biotechnol* 7:1–9.
17 <https://doi.org/10.3389/fbioe.2019.00397>
- 18 44. Swartz JE, Smits HJG, Philippens MEP, et al (2022) Correlation and colocalization of HIF-1 α
19 and pimonidazole staining for hypoxia in laryngeal squamous cell carcinomas: A digital,
20 single-cell-based analysis. *Oral Oncol* 128:105862.
21 <https://doi.org/10.1016/j.oraloncology.2022.105862>
- 22 45. Podszun MC, Chung JY, Ylaya K, et al (2020) 4-HNE Immunohistochemistry and Image
23 Analysis for Detection of Lipid Peroxidation in Human Liver Samples Using Vitamin E
24 Treatment in NAFLD as a Proof of Concept. *J Histochem Cytochem* 68:635–643.
25 <https://doi.org/10.1369/0022155420946402>

- 1 46. Francque S, Verrijken A, Mertens I, et al (2010) Noncirrhotic human nonalcoholic fatty liver
2 disease induces portal hypertension in relation to the histological degree of steatosis. *Eur J*
3 *Gastroenterol Hepatol* 22:1449–1457. <https://doi.org/10.1097/MEG.0b013e32833f14a1>
- 4 47. Parthasarathy G, Revelo X, Malhi H (2020) Pathogenesis of Nonalcoholic Steatohepatitis: An
5 Overview. *Hepatol Commun* 4:478–492. <https://doi.org/10.1002/hep4.1479>
- 6 48. Peiseler M, Schwabe R, Hampe J, et al (2022) Immune mechanisms linking metabolic injury to
7 inflammation and fibrosis in fatty liver disease – novel insights into cellular communication
8 circuits. *J Hepatol* 77:1136–1160. <https://doi.org/10.1016/j.jhep.2022.06.012>
- 9 49. Doi Y, Tamura S, Nammo T, et al (2007) Development of complementary expression patterns
10 of E- and N-cadherin in the mouse liver. *Hepatol Res* 37:230–237.
11 <https://doi.org/10.1111/j.1872-034X.2007.00028.x>
- 12 50. Kisseleva T, Brenner D (2021) Molecular and cellular mechanisms of liver fibrosis and its
13 regression. *Nat Rev Gastroenterol Hepatol* 18:151–166. [https://doi.org/10.1038/s41575-020-](https://doi.org/10.1038/s41575-020-00372-7)
14 [00372-7](https://doi.org/10.1038/s41575-020-00372-7)
- 15 51. Machado MV, Michelotti GA, Xie G, et al (2015) Mouse models of diet-induced nonalcoholic
16 steatohepatitis reproduce the heterogeneity of the human disease. *PLoS One* 10:1–16.
17 <https://doi.org/10.1371/journal.pone.0127991>
- 18 52. Sabattini E, Bisgaard K, Ascani S, et al (1998) The EnVision(TM)+ system: A new
19 immunohistochemical method for diagnostics and research. Critical comparison with the
20 APAAP, ChemMate(TM), CSA, LABC, and SABC techniques. *J Clin Pathol* 51:506–511.
21 <https://doi.org/10.1136/jcp.51.7.506>

22

23

1 **Figure legends**

2 **Figure 1. Representative pictures of immunohistochemistry (IHC) and reconstructed liver lobules**
3 **in C57BL/6J mice fed the choline-deficient L-amino acid-defined high-fat diet (CDAHFD) or**
4 **standard diet (control) for three weeks.** (A) Representative images of IHC for pimonidazole adducts
5 (Pimo) and glutamine synthetase (GS), and lipid vacuoles from macrovesicular steatosis (annotated in
6 blue). Pimonidazole is present around centrilobular veins in controls but displays panlobular
7 distribution in CDAHFD. The enzyme GS is expressed in centrilobular hepatocytes. (B) The upper
8 panel shows representative images of deconvoluted DAB signal for Pimo adducts, presented with the
9 pseudocolour image 'Red Hot'. Next, the lower panel displays reconstructed lobules in whole slide liver
10 images with centrilobular veins displayed in white. Each pixel in the whole liver slide received a value
11 ranging from 0 (edge of lobule) to 1 (the centrilobular vein) which represents its relative distance within
12 the constructed liver lobule. Each colour of the look-up table '16 colors' shows points at the same
13 relative distance between the centre and lobular edge (annotated in black) within these lobules.

14 **Figure 2. Zonated quantification of Pimonidazole immunohistochemistry in a mouse model of**
15 **non-alcoholic steatohepatitis (NASH) vs. normal livers.** (A) The percentage of Pimo positive area is
16 calculated at eleven points of relative distance from centre to edge within each lobule on the x-axis. The
17 graph represents the trend in Pimo IHC along the sinusoid in over 700 liver lobules from all laboratory
18 animals included in this study (NASH vs controls) (n=6). (B) Y-axis in this graph represents the
19 proportion of surface occupied by macrovesicular steatosis, as annotated in Fig. 1A middle panel. (C)
20 After exclusion of lipid vacuoles, the percentage of pimonidazole positive area is significantly higher in
21 the periportal zone in CDAHFD compared to controls. (D) The ratio of pimonidazole positive area in
22 periportal (PP) vs. centrilobular (CL) regions is compared in healthy and NASH subjects. Results are
23 presented as mean \pm standard deviation. Mann-Whitney U test; **p<0.01, ***p<0.001. Scale bar
24 represents 200 μ m or 1000 μ m.

25 **Figure 3. Zonated quantification of immunohistochemistry (IHC) in centro-central tracts of**
26 **'digital' liver biopsies in C57BL/6J mice fed the choline-deficient L-amino acid-defined high-fat**
27 **diet (CDAHFD) or standard diet (control) for three weeks.** (A) Representative images of a 'digital'

1 biopsy in control liver stained with IHC for pimonidazole adducts (Pimo). Relative distances within
2 lobules were reconstructed in the digital biopsy and the staining pattern of Pimo was assessed in the
3 parenchyma directly connecting different centrolobular veins, termed centro-central tracts (black
4 rectangles). (B) Y-axis in this graph represents the proportion of Pimo positive area in centro-central
5 tracts of digital liver biopsies from NASH and controls (n=12). The latter display centrolobular positivity
6 for this hypoxia marker. (C) After exclusion of lipid vacuoles, the percentage of pimonidazole positive
7 area is significantly higher in the periportal zone in CDAHFD compared to controls ($p < 0.05$). Hence,
8 the quantification in centro-central tracts detected the same trends as evaluation in whole liver slides
9 (Fig. 2). Results are presented as mean \pm standard deviation. Mann-Whitney U test; * $p < 0.05$. Scale bar
10 represents $\pm 200\mu\text{m}$.

11 **Figure 4. Quantification of immunohistochemistry for carbonic anhydrase IX in human liver**
12 **resection specimen with steatosis.** (A) Immunohistochemistry for carbonic anhydrase IX (CAIX)
13 revealed foci of strong positivity in a human resection specimen with steatosis. (B) Subjective evaluation
14 of the inset of this image reveals that positivity for CAIX is mainly located near centrolobular veins in
15 this specimen. (C) Annotated centrolobular veins (white dots) acted as references to reconstruct whole
16 liver lobules. Of note, lobules near the edge of the specimen were excluded from further analysis, since
17 the relative distance is less reliable there. (D) The positivity for CAIX (on y-axis) was plotted against
18 the relative distance in liver lobules (on x-axis). The curve visualises the zonal distribution of hypoxia
19 marker CAIX in this liver resection specimen. Scale bar represents 5mm or 200 μm .

20 **Figure 5. Proof-of-concept: study of the staining pattern of carbonic anhydrase IX in centro-**
21 **central tracts in human percutaneous liver biopsies with nonalcoholic steatohepatitis (NASH) or**
22 **control.** (A) Immunohistochemistry for carbonic anhydrase IX (CAIX) revealed more intense positivity
23 in all lobular zones in percutaneous liver biopsy material of two NASH patients (NASH1 and NASH2)
24 compared to control (upper panel). Next, we constructed the relative distance in the parenchyma
25 spanning between centrolobular veins, termed the centro-central tracts (lower panel). (B) Zonal
26 quantification of CAIX positivity in those centro-central tracts confirmed increased positivity of the
27 hypoxia marker in specimens with NASH, compared to control, and illustrates differences between


1 NASH patients. After exclusion of lipid vacuoles from analysis, the curves of NASH specimens shift
2 slightly upward (dashed lines). Scale bar represents 10 μ m or 20 μ m.

3

1 **Figures**

2 **Figure 1.**

Figure 1




3

4


5 **Figure 2.**

Figure 2




6



1 **Figure 3.**



3 **Figure 4.**



5 **Figure 5.**



1

2